• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities

    12/23/24 8:00:00 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZIVO alert in real time by email

    Expects to enter into formal negotiations with a global animal health company in January 2025 and to finalize an agreement in the first quarter of 2025

    Zivo Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens.

    Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions with a number of major global animal health companies regarding a potential exclusive license for ZIVO's product. Prospective licensees are actively pursuing their respective due diligence processes, including technical evaluations, patent reviews and business case assessments.

    Assuming the satisfactory completion of due diligence, ZIVO expects to enter into formal negotiations next month with the goal of finalizing an agreement in the first quarter of 2025. ZIVO intends to pursue deal terms that includes an upfront payment, milestone payments tied to commercialization targets and a royalty based on product sales.

    "We are focused on securing an agreement that aligns with our commercialization strategy and delivers long-term value to our shareholders. Although our license dialogues remain ongoing and there can be no assurance we will be successful in negotiating a definitive agreement, we are highly encouraged by the progress we have made over the past four months and by the level of interest expressed by prospective partners. Our product holds potential as a standalone treatment and also can enhance the efficacy of ionophores and vaccines, representing a compelling and transformative value proposition for the poultry industry," said John B. Payne, Chairman and Chief Executive Officer of ZIVO Biosciences.

    In addition, building upon last week's announcement of preliminary efficacy against avian influenza in poultry, the Company reports that it intends to advance development work on its product candidate targeting transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry flocks. ZIVO plans to initiate additional studies at the University of Delaware to further optimize dosage and formulation, with the goal of maximizing the product's efficacy and market readiness.

    "To date our active ingredients have demonstrated effectiveness against both parasitic and viral diseases. This remarkable versatility provides distinct commercial opportunities, including as a combination product in viral indications," added Mr. Payne.

    About Coccidiosis

    Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, with the estimated annual costs in excess of $15 billion annually. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spent approximately $1.1 billion in 2024, and is estimated to grow to $1.5 billion in 2029, on coccidiosis control, primarily using decades-old compounds that industry and consumers alike want to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.

    About ZIVO Bioscience

    Zivo Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.

    Forward Looking Statements

    Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company's product candidate's potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241223509640/en/

    Get the next $ZIVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZIVO

    DatePrice TargetRatingAnalyst
    12/15/2021$9.00Buy
    Maxim Group
    More analyst ratings

    $ZIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Zivo Bioscience with a new price target

      Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00

      12/15/21 10:56:47 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Zivo Bioscience Inc.

      SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

      10/1/24 2:57:20 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Zivo Bioscience Inc.

      SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

      6/12/24 8:49:08 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Zivo Bioscience Inc.

      SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

      6/12/24 8:44:12 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

      ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirm

      5/6/25 5:54:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

      ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. ZIVO's previous study with the University of Delaware demonstrated a significant reduction in viral shedding and a delay in disease transmission among treated birds. This new study is designed to further optimize formul

      2/6/25 4:36:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIVO Bioscience to Present at The Microcap Conference 2025

      Zivo Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities. Event: The Microcap Conference 2025 Location: Studio 1, Borgata Hotel Casino & Spa Date: Thursday January 30, 2025 Time: 2:30 PM Eastern Time Investors i

      1/22/25 4:15:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yaldoo Laith L bought $176,682 worth of shares (10,080 units at $17.53) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/4/25 8:23:32 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Strome Mark E bought $1,514,250 worth of shares (75,000 units at $20.19) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      12/31/24 6:47:29 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yaldoo Laith L bought $49,993 worth of shares (3,133 units at $15.96) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      10/17/24 7:33:33 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Maggiore Christopher D. sold $325 worth of shares (20 units at $16.25), decreasing direct ownership by 0.00% to 507,000 units (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/9/25 9:42:34 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yaldoo Laith L bought $176,682 worth of shares (10,080 units at $17.53) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/4/25 8:23:32 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 5 filed by Strome Mark E

      5 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/23/25 7:48:25 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Financials

    Live finance-specific insights

    See more

    $ZIVO
    SEC Filings

    See more
    • ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business

      ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products Conference call to be held in early November Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company's corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company's prop

      10/24/22 4:15:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Zivo Bioscience Inc.

      DEF 14A - Zivo Bioscience, Inc. (0001101026) (Filer)

      4/25/25 4:36:25 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zivo Bioscience Inc.

      DEFA14A - Zivo Bioscience, Inc. (0001101026) (Filer)

      4/25/25 8:30:43 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Zivo Bioscience Inc.

      10-K - Zivo Bioscience, Inc. (0001101026) (Filer)

      3/18/25 4:10:47 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care